Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals Plc ADR (NQ: CNTA )

15.67 +0.33 (+2.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 611,912
Open 15.28
Bid (Size) 14.80 (1)
Ask (Size) 15.83 (1)
Prev. Close 15.34
Today's Range 15.20 - 15.93
52wk Range 5.150 - 17.59
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire

Performance

YTD
+95.14%
+95.14%
1 Month
+12.57%
+12.57%
3 Month
+74.30%
+74.30%
6 Month
+41.17%
+41.17%
1 Year
+158.58%
+158.58%

More News

Read More
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers
Via Benzinga
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
Via Investor's Business Daily
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
CNTA Stock Earnings: Centessa Pharmaceuticals Misses EPS for Q2 2024
Via InvestorPlace
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023
Via InvestorPlace
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Via InvestorPlace
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.